Myriad Genetics Announces Incorporation of its Proprietary HRD platform in Illumina’s Updated Comprehensive Gene Panel Assay, TruSight™ Oncology 500 v2 Myriad Genetics announces incorporation of its proprietary HRD platform in Illumina’s updated comprehensive gene panel assay, TruSight™ Oncology 500 v2.

Myriad Genetics Collaborates with GSK to Improve Access to HRD Testing in 9 Countries SALT LAKE CITY, June 11, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a collaboration with GSK aimed at...

Global PARP Inhibitor Biomarkers Market to Surpass US$ 2,170.3 Million by 2027, Says CMI SEATTLE, April 13, 2020 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global PARP inhibitor biomarkers market is valued at US$ 374.9 million in 2019, and is projected to exhibit a...